|Articles|March 1, 2004

Volume 0

Seal•ON

Alltracel Pharmaceuticals (Dublin, Ireland) has announced the US launch of its new Seal?ON line of consumer first aid products. These products stop bleeding fast with the patented, clinically proven hemostatic agent m?doc (micro-dispersed oxidized cellulose). M?doc is a natural powdered hemostatic substance derived from pure cotton that helps stop bleeding from minor wounds, scrapes, and nosebleeds. It is pH-balanced, biocompatible, and hypoallergenic, so it will not irritate skin or cause an allergic reaction when applied to an open wound. Seal?ON is the first US first aid brand to feature m?doc. Seal?ON products include a spray, nasal sponges, and bandages. For more information, visit www.seal-on.com.

Articles in this issue

over 22 years ago

Article

Interface Speeds Up Prescription Filling

over 22 years ago

Article

New Technologies Top Survey

over 22 years ago

Article

Partnership Addresses Packaging Solutions

over 22 years ago

Article

PDX Software Gets High Marks

over 22 years ago

Article

Polar Powder Cold Pak with Magnetic Therapy

over 22 years ago

Article

SaltAire Sinus Relief

over 22 years ago

Article

Zim's Crack Creme Hand Sanitizer

over 22 years ago

Article

CoroWise Plant Sterols

over 22 years ago

Article

Culturelle

over 22 years ago

Article

Curad Scar Therapy Cosmetic Pads

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Latest CME

Virtual Event

Breast Cancer Day of Education 2026

Tuesday, July 14, 2026

Virtual Event

Neuropsychiatry Day of Education 2026

Thursday, July 16, 2026

Seal&#8226;ON

Articles in this issue

Related Content

Managing Grade 1 CRS in Patients With Follicular Lymphoma on Bispecific Antibodies: Home vs Health Care Facility Referred

Improve Skin Health Through Student Pharmacist Education

A Tower Of Medication Shortages: Leveraging Medication Repackaging Automation and Adaptive Staffing Strategies

MRD as a Therapeutic Compass: Pharmacists at the Helm of Adaptive Oncology

Vigilance in an Age of Misinformation: Rebuilding Trust Through Evidence and Connection

Latest CME

Breast Cancer Day of Education 2026

Neuropsychiatry Day of Education 2026

Innovations in Retinal Therapies: A Managed Care Perspective on Anti-VEGF Advancements

Stimulant Stewardship: A Pharmacist’s Guide to ADHD Prescribing During Drug Shortages

Improving Outcomes in Lipid Management: Aligning Managed Care Policy With Emerging Guideline Updates and Non-Statin Therapeutic Advances

From Evidence to Access: Integrating SGLT2 Inhibitors Across the Cardiorenal-Metabolic Continuum

Multidisciplinary Insights and Strategies for Patients Treated With PI3K and AKT Inhibitors to Prevent Hyperglycemia

Bridging Innovation and Access in HR-Positive/HER2-Negative Metastatic Breast Cancer: Implications for Managed Care

Cardiorenal Protection With SGLT2 Inhibitors: Perspectives for Managed Care

Navigating Advanced Prostate Cancer Treatment: Optimizing Novel Therapeutic Strategies for Managed Care Pharmacists

Advancing Treatment Strategies in Extensive-Stage Small Cell Lung Cancer: Enhancing Pharmacist Competence in Therapy Selection, Administration, and Adverse Event Management

Beyond the Nasal Passage: Managing Chronic Rhinosinusitis With Nasal Polyps With Biologics and Pharmacist-Led Approaches

Transforming Gout Care: Navigating Barriers and Therapeutic Advances in Disease Management

Pharmacists at the Forefront: Enhancing Targeted Therapy Implementation and Patient Outcomes in Advanced Gastric Cancer

Managing Overactive Bladder in Older Adults: Challenges and Strategies for Long-Term Care

Bridging Clinical and Access Gaps in Phenylketonuria: A Managed Care Perspective

Enhancing The Role of Oncology Pharmacists in Multidisciplinary Myeloproliferative Neoplasm Care

Biomarker Testing in Practice: Navigating Modalities and Multidisciplinary Decision-Making

HER2-Positive Metastatic Breast Cancer: A Managed Care Perspective on Emerging Therapies and Clinical Data

Collaborative Practice Agreement Implementation and Adherence: A Practical Roadmap for Oncology Pharmacists

Best Practice Approaches for Understanding Chronic Obstructive Pulmonary Disease and Precision Medicine Treatment

Exploring Immunotherapy Strategies in Endometrial Cancer

Advancing the Idiopathic Pulmonary Fibrosis Treatment Landscape: What’s Next in Care

From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Managing Steroid-Refractory Chronic Graft-versus-Host Disease With Novel Therapies: Opportunities for Pharmacist-Led Interventions

Sugar, We’re Going Down: Navigating Glycemic Control in the Era of PI3K/AKT Inhibition for Breast Cancer

Advancing Patient Safety: Strategies to Address Safety Risks and Adherence Barriers to Optimize Outcomes for Patients on Injectable Therapies

Redefining Metabolic Dysfunction-Associated Steatohepatitis Treatment: Managed Care Insights on New Therapies Targeting Metabolic Dysfunction

Directions in Pharmacy 2026

Not All Bispecifics Are Equal: Mechanism-Based Approaches to Selection and Management in Oncology Practice

Oncology Pharmacists Connect 2026

The Educated Pharmacist: Using Patient Insights to Personalize Insulin Therapy and Prevent Clinical Inertia

Breast Cancer Day of Education 2026

Outsmart the Algorithm: Combatting Misinformation at the Pharmacy Counter

Translating KDIGO Updates and Clinical Evidence Into Managed Care Decision-Making in IgA Nephropathy

Precision Matters: Foundations of Biomarker-Driven Care in Non-Small Cell Lung Cancer

Addressing Gaps in Care for the Rapid and Long-Term Management of Hyperkalemia With Novel Oral Potassium Binding Agents: Insights for Managed Care Professionals

Payment for Pharmacist Services: 2025 Update

The Oncology Pharmacist's Role in Managing Small Molecule Inhibitor Use in Chronic Lymphocytic Leukemia to Enhance Patient-Centered Care

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape

Advancing Pharmacist Expertise in R/R FL: Navigating Novel Therapies and Optimizing Patient Outcomes

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Navigating Novel Therapies in Steroid-Refractory cGVHD: Practical Strategies for Community-Based Oncology Pharmacists

Reducing Transfusion Burden in Myeloid Disorders: Novel Therapeutic Strategies and Pharmacist Interventions

Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Optimizing Patient Outcomes in R/R DLBCL: Bridging Knowledge Gaps for Oncology Pharmacists in the Era of Novel Immunotherapies

Clinical Panel Debate: CAR T-Cell Therapy vs Bispecific Antibodies

From Molecules to Medicine: Pharmacologic Principles of Innovative Non-Hodgkin Lymphoma Therapies

The Pharmacist's Role in Palliative and End of Life Symptom Management (Pharmacy Technician Credit)

Navigating the Legal Landscape of Telehealth: Updates and Implications for Pharmacists and Technicians

Reducing the Treatment Burden in HIV Management: The Pharmacist’s Role in Long-Acting Injectable Adoption

Protecting Against Meningococcal Disease: Updates on Vaccines, Guidelines, and Pharmacist Best Practices

Targeting the Root of Autoimmunity in Generalized Myasthenia Gravis: Pharmacist Strategies for Integrating FcRn Therapies Into Specialty Practice

IL-23 Inhibitors in Psoriasis: Optimizing Access and Patient Outcomes Across Integrated Systems

Utilizing VMAT-2 Inhibitors for the Management of Tardive Dyskinesia: The Role of Long-Term Care Pharmacists

Influenza Immunization in Older Adults: Enhanced Vaccines and Best Practices for Long-Term Care Pharmacists

Shaping the Future of Generalized Myasthenia Gravis Management: A Focus on Novel Treatment Approaches

From Flares to Freedom: Navigating the Journey of Patients With Chronic Spontaneous Urticaria With Next-Generation Therapies

Understanding Type 2 Inflammation and Its Role Across Various Immune-Related Diseases

Chronic Obstructive Pulmonary Disease and Inflammation: Practical Approaches to Integrating Biologic Therapy

Type 2 Inflammation in Focus: Advancing Pediatric Atopic Dermatitis Care With Biologic Therapies

Innovations in Lymphoma Treatment and the Growing Impact of Bispecific Antibodies

Addressing the Burden of Hemolysis in Paroxysmal Nocturnal Hemoglobinuria: The Pharmacist's Contribution to Patient Care

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

Targeting Genomic Drivers to Optimize ROS1-Directed Therapy in NSCLC

From Molecule to Medication: Integrating Menin Inhibitors in AML Practice

Adapting to Advances in EGFR-Positive Non-Small Cell Lung Cancer Treatment: Critical Insights for Oncology Pharmacists

VMAT2 Inhibitors for Long-Term Success in Tardive Dyskinesia

Breaking Barriers in Asthma Care: Exploring the Role of Type 2 Inflammation and Biologic Therapies

Redefining Complement-Mediated Kidney Disease: The Latest in Diagnosis and Treatment

The Pharmacist's Role in Palliative and End of Life Symptom Management

Seal•ON